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Summary
AIMS OF THE STUDY: To describe the characteristics
of cases presenting at the emergency department due to
(suspected) poisoning for which consultation on patient
management with the national Poisons Information Centre
was required.
METHODS: Retrospective study at the emergency de-
partment of Bern University Hospital, Switzerland, from
May 2012 to December 2017. Cases were identified in
the electronic patient database using appropriate full-text
search terms. Cases were excluded if the contact with the
National Poisons Information Centre was through an ex-
ternal hospital or directly by the patient. Cases in which
the poison centre was not contacted and cases without the
patient’s general consent to use their medical data for re-
search purposes were also excluded.
RESULTS: Overall, 667 cases from the study period were
included. The median age was 32 years (range 16–94);
405 patients (61%) were female and 262 (39%) male.
In most cases, the poisoning was acute (n = 631, 95%)
and intentional (n = 505, 76%). The most common route
of exposure was ingestion (n = 587, 88%) and the most
commonly involved substances were sedatives (n = 185,
28%), antidepressants (n = 162, 24%) and non-opioid
analgesics (n = 161, 24%). Impaired consciousness was
documented in 299 cases (45%). Approximately half of the
cases (n = 359, 54%) were of minor severity as assessed
using the Poisoning Severity Score, 142 (21%) were of
moderate severity, 110 (16%) were asymptomatic and 56
(8%) were severe. There were no fatalities. In most cas-
es (n = 599, 90%), immediate therapeutic or diagnostic
measures were undertaken prior to contact with the poison
centre. Decontamination measures and specific antidotes
undertaken or administered only after contacting the poi-
son centre included whole bowel irrigation, haemodialysis,
fomepizole, biperiden, silibinin, deferoxamine, leucovorin,
dimercaptopropanesulfonic acid and hydroxocobalamin.
Administration of a specific antidote/therapeutic agent was
recommended in 87 cases (13%). In 70 of these 87 cases
(80%), the specific agents were administered as recom-
mended by the poison centre. In 17 cases (20%), the spe-
cific antidotes were not administered as recommended be-
cause of either clinical improvement (n = 11), termination
of therapy based on laboratory results (n = 3), therapy re-
fused by the patient (n = 2), or identification of a mush-
room as non-poisonous (n = 1). In 109 cases (16%), there
was no change in patient management after contacting the
poison centre.
CONCLUSIONS: For patients presenting at the emer-
gency department with severe poisoning, contact with the
poison information centre can help to implement specific
treatment and avoid fatalities. In less severe cases in-
volving more common agents (e.g. paracetamol, benzo-
diazepines), contact can help to avoid unnecessary treat-
ment and serve as a source of information and/or
confirmation.
Keywords: poisoning, intoxication, poison information
centre, emergency department, patient management
Introduction
Poisoning is a common reason for patients to present at the
emergency department (ED). According to data from Euro-
pean hospitals [1, 2], about 1% of all ED admissions are re-
lated to poisoning. Although this does not seem very high
at first glance, it constitutes an important component when
the risk of a potentially fatal outcome in many of these
cases is considered. Poison information centres (PICs) can
provide valuable support to ED personnel and help to opti-
mise patient management in such cases. In Switzerland, the
official information point for all poisoning cases is Tox In-
fo Suisse. Tox Info Suisse has extensive documentation on
chemicals, drugs, poisonous plants and animals, food and
other products, and offers 24-hour telephone information.
PICs are contacted in about one out of every four cases of
poisoning [3], with lower rates in fatal cases [4, 5].
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The treatment of poisoning depends on the specific case.
In some cases, solely supportive measures (e.g., adminis-
tration of oxygen, intravenous fluids) may be sufficient to
adequately treat the patient, whereas in other cases the ad-
ministration of a specific antidote (e.g., naloxone in the
case of opioid poisoning [6]) and/or decontamination mea-
sures (e.g., administration of activated charcoal to adsorb
toxins in the digestive tract) are indicated. For certain com-
mon agents (e.g., paracetamol [7]), the indicated imme-
diate measures are often part of the hospital’s emergency
protocols – in the form of specific schemes, treatment algo-
rithms or nomograms [8] – and are widely known among
physicians and ED personnel, as they are part of basic
medical education. However, for many other less common
agents, or if the toxicant is not known to the attending
physician, the procedure is less systematic. Since time is a
factor of great importance in poisoning cases, consultation
of PIC specialists in such cases can be lifesaving.
The aim of the present study was to describe the charac-
teristics of cases presenting at the ED due to poisoning for
which consultation of the national PIC on patient manage-
ment was needed. Our findings should help to optimise the
management of poisoned patients at the ED by providing
an overview of cases which required consultation of a toxi-
cology specialist and a basis for the updating of emergency
treatment protocols.
Materials and methods
This was a retrospective single centre study at the ED of
the University Hospital of Bern, Switzerland, from May
2012 to December 2017. The ED of the University Hos-
pital of Bern serves as both a primary care facility (walk-
in patients) and a tertiary referral centre for other hospitals
in the region (for patients ≥16 years of age). It serves a
catchment area of approximately two million people and
has about 48,000 emergency admissions a year (2018).
All patient data collected during routine clinical care at the
ED is stored in the electronic database E.care. In order to
identify relevant patients for whom the ED contacted the
PIC, E.care was searched using appropriate full-text search
terms (e.g., poison centre, poison information centre, Tox
Info Suisse). Each identified case was reviewed by one of
the study authors. We included all cases of patients pre-
senting at the ED due to (suspected) poisoning during the
study period and for whom the PIC was contacted by the
ED. We excluded cases in which the PIC was contacted by
an external hospital or by the patients themselves, as well
as cases in which the PIC was not contacted, cases where
the patient had not given general consent to the use of their
medical data for research purposes, or cases for which in-
sufficient information was available.
The following data were exported (if available) from
E.care for the analyses: sex, age, type of transport to the
ED (e.g., by ambulance), date and time of presentation and
onset of symptoms, clinical symptoms and severity of poi-
soning, type of treatment (inpatient versus outpatient), tox-
icological laboratory values, documented specific recom-
mendations of PIC specialists, and management before and
after contact with the PIC. The category “diagnostic deci-
sion” included PIC recommendations for blood tests, drug
concentration measurements, toxicological screening and
computed tomography scans. Patients admitted at the ED
at the same time due to exposure to the same agent(s) were
regarded as forming a single cluster. Night arrival was de-
fined as ED presentation between 20:00 and 08:00, and
weekend arrival as presentation between 17:00 on Friday
and 08:00 on Monday. Based on the definitions used by
Tox Info Suisse and the American Association of Poison
Control Centers [9, 10], acute exposure was defined as sin-
gle, repeated or continuous exposure occurring over eight
hours or less, and chronic exposure as continuous or re-
peated exposure occurring over >8 hours. The classifica-
tion of the involved agents into groups was also based on
the substance categories used by the American Associa-
tion of Poison Control Centers [9]. Urine drug screening
(when available) was performed using an immunoassay
test (Triage® TOX Drug Screen, Alere, Cologne, Ger-
many) to screen for amphetamines, barbiturates, benzodi-
azepines, cocaine, methadone, methamphetamines (includ-
ing MDMA), opiates, paracetamol, phencyclidine (PCP),
tricyclic antidepressants and tetrahydrocannabinol
(cannabis). The severity of poisoning was assessed using
the Poisoning Severity Score to grade acute poisoning [11].
Results
A total of 821 potential cases were initially retrieved using
the full-text search terms. Of these, 154 cases had to be ex-
cluded, either because they failed to meet our inclusion cri-
teria (n = 124) or because the patient’s general consent to
use their medical data for research purposes was absent (n
= 30). Finally, 667 cases were included in the final analy-
sis, including 21 patients in nine clusters.
The median age of the study population was 32 years
(range 16–94). Of the 667 patients, 405 (61%) were female
and 262 (39%) male. The majority of the patients were
Swiss (n = 513, 77%) and the mean (±SD) duration of stay
at the ED was 7 ± 7 hours. The annual and monthly dis-
tributions of the cases over the study period are shown in
figure 1. Table 1 shows the characteristics of the cases.
In 53 of the 667 cases (8%), the incident was an occupa-
tional accident. In 470 cases (70%), a psychiatric disease
was documented in the medical history. Figure 2 shows the
agents/substances involved. The category “others (medica-
tion)” included the following agents/substances: allopuri-
nol, antidiabetic, antimalarial and anti-Parkinson agents,
chlorhexidine, clomethiazole, colchicine, disulfiram, flu-
orouracil, immunosuppressants, memantine, oxybutynin,
thyroid and other hormones, Fenipic® (an over-the-counter
product for insect bites or other skin irritations), a product
sold online for penis enlargement, and a veterinary drug.
The category “others (non-medication)” included ammo-
nia, batteries, caffeine, diesel, kerosene, mercury, nicotine,
pork liver, potassium cyanide, potassium permanganate
and propane. Common clinical features of the cases are
shown in table 2. Table 3 presents an overview of patient
management before and after contacting the PIC, as well
as the specific recommendations of the consultation.
In 237 cases, toxicological drug screening was performed
before contact with Tox Info Suisse. This was positive for
benzodiazepines in 87, cannabis in 40, paracetamol in 37,
opiates in 24, cocaine in 15, tricyclic antidepressants in 15,
methadone in 7, methamphetamine in 4 and barbiturates in
4 cases (some cases were positive for more than one sub-
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Figure 1: Annual (a) and monthly (b) distributions of the cases for
which contact with the Poisons Information Centre was undertaken
at the emergency department (N = 667).
stance). The test was negative in 71 cases, and in 27 cases
the results were not specified in the report.
Table 4 shows the specific antidotes and therapeutic agents
administered at the ED prior to contacting the PIC, as
well as the specific antidotes/agents recommended by Tox
Info Suisse and those administered after the consultation
without specific recommendation by the PIC. The specific
agents were administered as recommended by Tox Info Su-
isse in 70 cases. In 17 cases, the specific agents were not
administered as recommended by the Tox Info Suisse be-
cause either the measures already taken were sufficient to
lead to clinical improvement (n = 11), the therapy was
stopped on the basis of laboratory results (e.g., drug con-
centrations) (n = 3), the therapy was refused by the patient
(n = 2), or a mushroom was identified by a mushroom ex-
pert as one that does not contain amatoxin (n = 1).
Table 5 shows an overview of the decontamination proce-
dures that were recommended and/or performed before or
Table 1: Case characteristics (N = 667).
n (%)
Time of admission Night arrival 296 (44)
Weekend arrival 236 (35)
Type of admission By ambulance 436 (65)
Self-admission 210 (31)
By Swiss air-ambulance 21 (3)
Route of exposure Ingestion 587 (88)
Inhalation/nasal 44 (7)
Transdermal 26 (4)
Bite/sting 10 (1)
Ocular 8 (1)
Injection 7 (1)
Unknown 2 (<1)
Circumstances of exposure Intentional 505 (76)
Suicidal 427 (64)
Misuse 46 (7)
Abuse 32 (5)
Unintentional 162 (24)
Accident 116 (17)
Therapeutic error 42 (6)
Adverse reaction 1 (<1)
Unknown 3 (<1)
Chronicity Acute 631 (95)
Chronic 36 (5)
Number of agents involved Multiple 345 (52)
Single 321 (48)
Unknown 1 (<1)
Time from exposure until ED admission <1 hour 67 (10)
1–4 hours 279 (42)
5–12 hours 98 (15)
13–23 hours 29 (4)
>24 hours 19 (3)
Unknown 175 (26)
Poisoning Severity Score Minor 359 (54)
Moderate 142 (21)
Severe 56 (8)
Fatal 0 (0)
Not applicable (no symptoms) 110 (16)
Outcome Admitted to psychiatric hospital 247 (37)
Discharged home 212 (32)
Admitted to ICU 171 (26)
Admitted to ward other than ICU 37 (6)
ED = emergency department; ICU = intensive care unit
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after contacting the PIC. Administration of activated char-
coal was recommended by the PIC in 87 cases and was ad-
ministered after the consultation in 78 cases (table 5). In
seven cases in which it was recommended by the PIC, acti-
vated charcoal had already been administered prior to con-
sultation. A gastroscopy was recommended by the PIC in
30 cases. This had already been performed prior to con-
tact in one of these cases. Gastroscopy was performed after
consultation in 23 of the cases in which it was recommend-
ed by the PIC, as well as in eight additional cases. Whole
bowel irrigation was performed in five of the seven cases
Figure 2: Involved agents/substances by number of cases (more than one agent involved in some cases).
Table 2: Common clinical features in cases in which the emergency department contacted the poison information centre (N = 667).
n (%)
Nervous system Drowsiness / GCS 8–14 230 (34)
Coma / GCS 3–7 69 (10)
Mydriasis 61 (9)
Miosis 54 (8)
Vertigo 47 (7)
Agitation 28 (4)
Seizures 15 (2)
Cardiovascular system Tachycardia (heart rate >100 bpm) 152 (23)
ECG abnormalities 127 (19)
Bradycardia (heart rate <60 bpm) 16 (2)
Hypotension (systolic blood pressure <90 mm Hg) 16 (2)
Hypertension (systolic blood pressure >180 mm Hg) 10 (1)
Gastrointestinal tract Nausea/vomiting 128 (19)
Stomach ache 38 (6)
Diarrhoea 14 (2)
Respiratory system Hyperventilation (respiratory rate >20/min) 58 (9)
Hypoventilation 24 (4)
Dyspnoea 11 (2)
Other Local irritation/swelling 57 (9)
Anticholinergic toxidrome 11 (2)
Hyposecretion 10 (1)
Hypersecretion 8 (1)
Urinary retention 8 (1)
Extrapyramidal symptoms 3 (<1)
Hyperthermia (>39°C) 2 (<1)
Cholinergic toxidrome 2 (<1)
Serotonin syndrome 1 (<1)
ECG = electrocardiogram; GCS = Glasgow Coma Scale
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in which it was recommended, as well as in one additional
case (tables 3 and 5).
The PIC recommended cessation of the specific treatment
based on the paracetamol blood concentration in six cases,
on the seizure threshold in four cases with benzodiazepine
poisoning, on the opinion of the mushroom expert in one
case, and on the gastroscopy findings in one case of ammo-
nia poisoning. Of the 21 cases in which the specific treat-
ment was stopped after consulting the PIC (table 3), this
was based on the recommendation of the PIC in eight cas-
es. The specific treatment was continued despite the rec-
ommendation to stop in six cases. These cases included
four for which flumazenil was continued because the pa-
tient was non-responsive and one case of acetylcysteine
treatment due to clinical suspicion of poisoning with mush-
rooms containing amatoxin (reason unclear in one case).
There were 13 additional cases in which the specific ther-
apy was stopped without an explicit recommendation from
the PIC. These included nine cases of paracetamol poison-
ing (acetylcysteine stopped on the basis of the paraceta-
mol blood concentration), four cases of mushroom poison-
ing (acetylcysteine (n = 2) and silibinin (n = 2) stopped
on the basis of negative amatoxin laboratory results), one
case of acetylsalicylic acid poisoning (sodium bicarbonate
stopped on the basis of the acetylsalicylic acid blood con-
centration), and one case of hydrofluoric acid in which cal-
cium gluconate was stopped due to the low concentration
of the solution.
Discussion
In this retrospective study at a large ED in Switzerland,
most cases requiring contact with the PIC involved rela-
tively young (median age 32 years) female patients with
known psychiatric co-morbidities presenting within four
hours after intentional ingestion of prescription drugs. Ap-
proximately half of the cases were of minor severity and
there were no fatalities (table 1). Approximately one third
of the patients were discharged home directly from the
ED, one third were admitted to a psychiatric hospital and
one fourth to the intensive care unit (table 1). In most
cases, therapeutic and/or diagnostic measures were initiat-
ed prior to contacting the PIC. Decontamination measures
and antidotes undertaken/administered only after contact-
ing the PIC included whole bowel irrigation, haemodial-
ysis, fomepizole, biperiden, silibinin, deferoxamine, leu-
covorin, dimercaptopropanesulfonic acid and
hydroxocobalamin. Only in 16% of cases was patient man-
agement unchanged after contacting the PIC (table 3).
A previous study in Switzerland identified the following
factors as being significantly associated with ED physi-
cians contacting the PIC [12]: female sex, ingestion of
more than one substance, and intentional poisoning. This is
consistent with our finding that most cases involved female
patients and intentional exposure (e.g., suicide attempts;
table 1). Greater doses are usually ingested in cases of in-
tentional poisoning [12], and most cases of attempted sui-
cide in Switzerland involve women and poisoning [13].
However, we found similar numbers of cases involving a
single and multiple substances (table 1). As in the previous
study [12], the PIC was sometimes contacted even though
the patients were asymptomatic (table 1). Reasons for this
might be exposure to uncommon agent(s), reassurance that
it was acceptable to discharge the patients [12], or as pre-
caution when it was expected that the patient would sub-
sequently develop symptoms (e.g., with presentation im-
mediately or very soon after exposure). In our study, most
patients presented on weekdays and during the day (table
1). Possible reasons for this might be that night-time and
weekend poisonings are often related to recreational drugs
and alcohol [12] and would not therfore require the consul-
tation of a specialist. Alternatively, it may be more difficult
for the ED team to contact the PIC during off-peak times,
as fewer medical staff are available.
In contrast to what one might have expected, most cases
for which the PIC was contacted involved commonly used
prescription drugs for which poisoning management is of-
ten known (e.g. flumazenil for benzodiazepine poisoning
[14], acetylcysteine for paracetamol poisoning [15]), rather
Table 3: Specific recommendations of the poison information centre and patient management before and after the consultation: n (%); N = 667.
Measure Management prior to consultation Specific recommendations Management after consultation
Only clinical examination 68 (10)
Monitoring/ECG 427 (64) 84 (13) 77 (12)
Blood test(s) 580 (87)
Urine tox screen 237 (36)
Blood drug concentration(s) 58 (9)
No specific treatment 547 (82) 132 (20)
Specific antidote/agent 77 (12) 87 (13) 86 (13)
Activated charcoal 32 (5) 87 (13) 78 (12)
Intubation 31 (5) 16 (2)
Topical decontamination 9 (1) 6 (1) 5 (1)
Gastroscopy 6 (1) 30 (4) 31 (5)
Whole bowel irrigation 7 (1) 6 (1)
Haemodialysis 3 (<1) 1 (<1)
Information regarding possible symptoms 469 (70)
Symptomatic therapy/ treatment if symptoms 203 (30) 144 (22)
Observation 295 (44) at ED: 306 (46)
at ICU: 165 (25)
Diagnostic decision 140 (21) 165 (25)
Stop specific treatment 14 (2) 21 (3)
No change in management 109 (16)
ECG = electrocardiogram; ED = emergency department; ICU = intensive care unit
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than unusual or less familiar substances or chemicals (fig.
2). It is possible that this is because these prescription
drugs are used very widely and are thus more likely to
cause poisoning than more rarely used agents such as
chemicals or plants. Another factor might be that in many
cases the clinical presentation, rather than the agent itself,
is the most important trigger for contacting the PIC. Our
findings indicate that the decision to contact the PIC is
more often influenced by impaired consciousness than by,
for example, sympathomimetic symptoms (impaired con-
sciousness (GCS <15) in 44% of cases in our study vs.,
e.g., agitation in 4%; table 2). The importance of the clin-
ical presentation is also highlighted by the cases in which
the specific antidotes and therapies were not administered
as recommended by the PIC, mainly due to clinical im-
provement.
Therapies/measures that were undertaken only after con-
tacting the PIC included decontamination procedures
(whole bowel irrigation [16], haemodialysis) and specific
antidotes (fomepizole, biperiden, silibinin, deferoxamine,
leucovorin, dimercaptopropanesulfonic acid and hydroxo-
cobalamin; tables 3 and 5). The procedures associated with
such measures are more complicated compared to alterna-
tives such as the administration of activated charcoal, and
the possible contraindications (e.g., ileus, haemodynamic
instability in the case of whole bowel irrigation [17]) and
complications might be among the reasons that these de-
contamination measures were not performed prior to con-
Table 4: Specific antidotes and therapeutic agents (left column) administered prior to consulting the poison centre, as well as those recommended by the poison centre or ad-
ministered without specific recommendation after the consultation (right column: number of cases for causative agents/symptoms).
Specific antidote/ therapeutic agent Causative agent/symptom (n)
Flumazenil Administered prior to consultation Benzodiazepines (n = 30), other (n = 4)
Recommended by the poison centre Benzodiazepines (n = 1; already administered prior to consultation)
Administered after consultation without specific rec-
ommendation
Benzodiazepines (n = 5)
Acetylcysteine Administered prior to consultation Paracetamol (n = 16), mushrooms (n = 2), other (n = 2)
Recommended by the poison centre Paracetamol (n = 33; already administered prior to consultation in 7 of
these cases), mushrooms (n = 10), other (n = 1)
Administered after consultation without specific rec-
ommendation
Paracetamol (n = 2)
Naloxone Administered prior to consultation Opioids (n = 7), other (n = 3)
Recommended by the poison centre Opioids (n = 4; already administered prior to consultation in 2 of these
cases)
Administered after consultation without specific rec-
ommendation
Opioids (n = 2)
Calcium gluconate Administered prior to consultation Hydrofluoric acid (n = 4)
Recommended by the poison centre Hydrofluoric acid (n = 1)
Sodium bicarbonate Administered prior to consultation Analgesic agent/acidosis (n = 2), cleaning agent/acidosis (n = 1)
Recommended by the poison centre Acetylsalicylic acid/coma (n = 3), acidosis (n = 3; already administered
prior to consultation in all 3 cases)
Ethanol Administered prior to consultation Ethylene glycol (n = 2)
Phytomenadione (vitamin K) Administered prior to consultation Anticoagulant (n = 1), rodenticide (n = 1)
Recommended by the poison centre Anticoagulant (n = 1)
Atropine Administered prior to consultation Pesticide/cholinergic toxidrome (n = 1)
Recommended by the poison centre Pesticide/cholinergic toxidrome (n = 2; already administered prior to
consultation in 1 case), mushrooms/coma (n = 1), other (n = 1)
Simeticone Administered prior to consultation Cleaning agent (n = 1)
Recommended by the poison centre Cleaning agent (n = 10)
Hypertonic amphoteric solution (Diphoterin®) Administered prior to consultation Alkaline solution (n = 1)
Magnesium Administered prior to consultation Antidepressants and neuroleptic agents / torsade de pointes (n = 1)
Administered after consultation without specific rec-
ommendation
Neuroleptic agents / prolonged QTc (n = 2), acetylsalicylic acid/hypo-
magnesaemia (n = 1)
Proton-pump inhibitor Administered prior to consultation Cleaning agent (n = 2)
Recommended by the poison centre Cleaning agent (n = 1)
Corticosteroids Administered prior to consultation Gastrointestinal swelling (n = 2)
Benzodiazepines Administered prior to consultation Caffeine (n = 1), analgesic agent/seizures (n = 1)
Recommended by the poison centre Illicit drugs/agitation (n = 2), antidepressants / anticholinergic toxidrome
(n = 1)
Fomepizole Recommended by the poison centre Ethylene glycol (n = 4)
Biperiden Recommended by the poison centre Neuroleptic agent / extrapyramidal symptoms (n = 1)
Administered after consultation without specific rec-
ommendation
Neuroleptic agent / extrapyramidal symptoms (n = 1)
Silibinin Recommended by the poison centre Mushrooms (n = 10)
Deferoxamine Recommended by the poison centre Iron (n = 1)
Leucovorin Recommended by the poison centre Methotrexate (n = 1)
Dimercaptopropanesulfonic acid Recommended by the poison centre Mercury (n = 1)
Hydroxocobalamin Recommended by the poison centre Potassium cyanide / status epilepticus (n = 1)
Oxygen Recommended by the poison centre Dichlormethane (n = 1)
Physostigmine Administered after consultation without specific rec-
ommendation
Atropa belladonna / anticholinergic toxidrome (n = 1)
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Table 5: Decontamination procedures by agent (number of cases; more than one agent involved in some cases).
Involved agent Activated charcoal Gastroscopy Whole bowel irrigation Haemodialysis
Prior
(n = 32)
Rec.
(n = 87)
After
(n = 78)
Prior
(n = 6)
Rec.
(n = 30)
After
(n = 31)
Prior
(n = 0)
Rec.
(n = 7)
After
(n = 6)
Prior
(n = 0)
Rec.
(n = 3)
After
(n = 1)
Analgesics 14 16 14 2 6 4 2 1 2 1
Antidepressants 9 19 18 6 7 3 2 1
Sedatives 7 17 15 1 10 11 2 2 2
Anticonvulsants 6 6 6 2 3 1 1 1
Neuroleptics 6 25 23 1 9 11 2 2
Alcohol 5 18 13 1 3 3 2 2
Fungi 4 10 9 1 1
Cardiovascular drugs 3 5 2 2 1 1 1 1
Opioids 2 7 6 2 2 1
Antihistamines 1 2 2
Muscle Relaxants 1 2 2
Cleaning agents 1 2 5 5
Plants 1 14 12 3 7 7
Dextromethorphan 2 1
Laxatives 1
Illicit drugs 2 1 1 1
Lithium 2 1 4 3
Cosmetics 1
Ammonia 1 2
Other 3 10 7 4 3 2 3
After = after consultation; Prior = before consultation; Rec. = recommended
tacting the PIC. Among the antidotes, the alcohol dehy-
drogenase inhibitor fomepizole is the preferred therapy in
cases of methanol and ethylene glycol poisoning, although
ethanol might also be used and was indeed administered
prior to contacting the PIC in two of the ethylene glycol
poisoning cases in our study. Antidotes such as the milk
thistle extract silibinin [18, 19], the chelating agents defer-
oxamine and dimercaptopropanesulfonic acid, and hydrox-
ocobalamin [20, 21] are less well known than, for exam-
ple, acetylcysteine for paracetamol or naloxone for opioid
poisoning. They are, however, among the most important
antidotes for acute poisoning [21]. It is thus an advan-
tage if these substances are readily available in the ED and
if physicians are familiar with their use. The anticholin-
ergic agent biperiden can be useful against extrapyrami-
dal symptoms after poisoning with neuroleptics (howev-
er, alternative treatments such as amantadine have been
shown to be as effective as anticholinergic agents, but
with fewer adverse effects [22]). The reduced folate leu-
covorin (also called folinic acid) can be administered to
decrease the toxic effects of high-dose therapy with the
folate antimetabolite methotrexate. Since leucovorin can
only rescue cells that do not already have lethal DNA dam-
age, treatment must be initiated within 24 to 36 hours to
be effective [23]. Antidotes administered prior to contact
with the PIC included well known substances/antidotes
for common agents (e.g. flumazenil for benzodiazepines,
acetylcysteine for paracetamol, naloxone for opioids and
vitamin K for anticoagulant poisoning), but also some less
commonly used and often not readily available substances,
such as calcium gluconate (used as treatment for hydroflu-
oric acid burns; calcium ions complex free fluoride ions)
and the antiflatulent simeticone (anti-foaming use in cases
involving surfactants, such as shampoo) [21]. In one case
with anticholinergic toxidrome, the acetylcholinesterase
inhibitor physostigmine was administered after contacting
the PIC but without an explicit recommendation (table 4).
Physostigmine (in contrast to other carbamates such as
neostigmine and pyridostigmine) crosses the blood-brain
barrier and is thus indicated in cases with both peripheral
and central anticholinergic toxicity. Although infrequent,
adverse effects include seizures and arrhythmias [24].
The limitations of our study include its retrospective de-
sign, missing information regarding the exact time lag be-
tween first contact at the ED and PIC contact, and missing
information on the long-term outcomes, especially for cas-
es admitted to a psychiatric hospital shortly after arrival
at the ED. Furthermore, in some cases specific decontami-
nation measures were recommended or indicated for some
but not all the agents involved, and some cases were not
included due to the lack of a general consent form or if
the PIC was contacted by an external hospital or by the
patients themselves. Also, data from one ED may not be
representative of the whole country. It cannot be exclud-
ed that the call to the PIC might not have been recorded
in some cases. although this is not expected since all mea-
sures regarding patients’ management and medical proce-
dures (including external consultations and treatment de-
cisions) are documented in detail in E.care for all cases
presenting at the ED. The strengths of this study include
the sensitive search and the individual review of each case.
Although previous studies from the United States have in-
vestigated the impact of PIC consultation on the reduction
of health-care costs and length of hospital stay [25–27],
this is to our knowledge the first study addressing the im-
pact of PIC consultation on ED patient management in
Switzerland, and it could thus contribute to the improve-
ment of ED procedures and patient care and provide a basis
for future prospective studies investigating not only specif-
ic medical aspects, but also economic ones.
In conclusion, cases requiring contact with the PIC in-
volved mainly acute, intentional poisoning with prescrip-
tion drugs, and the patients often presented with impaired
consciousness. Although in most cases therapeutic and/or
Original article Swiss Med Wkly. 2019;149:w20164
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diagnostic measures were initiated prior to contacting the
PIC, there were also decontamination measures and anti-
dotes undertaken or administered only after PIC consulta-
tion. In cases of severe poisoning, it is important that ED
physicians should contact the PIC. This helps them to im-
plement specific treatment measures and avoid fatalities.
Moreover, it reduces the likelihood of unnecessary treat-
ment measures and provides a source of information and/
or confirmation – particularly in less severe cases involv-
ing more common agents such as paracetamol and benzo-
diazepines.
Acknowledgements
We thank Rodney Yeates for his editorial assistance.
Disclosure statement
No financial support and no other potential conflict of interest relevant
to this article were reported.
References
1 Burillo-Putze G, Munne P, Dueñas A, Pinillos MA, Naveiro JM, Cobo
J, et al., Clinical Toxicology Working Group, Spanish Society of Emer-
gency Medicine (SEMESTOX). National multicentre study of acute in-
toxication in emergency departments of Spain. Eur J Emerg Med.
2003;10(2):101–4. doi: http://dx.doi.org/10.1097/
00063110-200306000-00006. PubMed.
2 Maignan M, Pommier P, Clot S, Saviuc P, Debaty G, Briot R, et al. De-
liberate drug poisoning with slight symptoms on admission: are there
predictive factors for intensive care unit referral? A three-year retrospec-
tive study. Basic Clin Pharmacol Toxicol. 2014;114(3):281–7. doi:
http://dx.doi.org/10.1111/bcpt.12132. PubMed.
3 Harchelroad F, Clark RF, Dean B, Krenzelok EP. Treated vs reported
toxic exposures: discrepancies between a poison control center and a
member hospital. Vet Hum Toxicol. 1990;32(2):156–9. PubMed.
4 Linakis JG, Frederick KA. Poisoning deaths not reported to the regional
poison control center. Ann Emerg Med. 1993;22(12):1822–8. doi:
http://dx.doi.org/10.1016/S0196-0644(05)80408-1. PubMed.
5 Blanc PD, Kearney TE, Olson KR. Underreporting of fatal cases to a re-
gional poison control center. West J Med. 1995;162(6):505–9. PubMed.
6 Kim HK, Nelson LS. Reversal of Opioid-Induced Ventilatory Depres-
sion Using Low-Dose Naloxone (0.04 mg): a Case Series. J Med Toxi-
col. 2016;12(1):107–10. doi: http://dx.doi.org/10.1007/
s13181-015-0499-3. PubMed.
7 Blieden M, Paramore LC, Shah D, Ben-Joseph R. A perspective on the
epidemiology of acetaminophen exposure and toxicity in the United
States. Expert Rev Clin Pharmacol. 2014;7(3):341–8. doi:
http://dx.doi.org/10.1586/17512433.2014.904744. PubMed.
8 Levine M, Stellpflug S, Pizon AF, Traub S, Vohra R, Wiegand T, et al.
Estimating the impact of adopting the revised United Kingdom aceta-
minophen treatment nomogram in the U.S. population. Clin Toxicol
(Phila). 2017;55(6):569–72. doi: http://dx.doi.org/10.1080/
15563650.2017.1291945. PubMed.
9 Gummin DD, Mowry JB, Spyker DA, Brooks DE, Osterthaler KM,
Banner W. 2017 Annual Report of the American Association of Poison
Control Centers’ National Poison Data System (NPDS): 35th Annual
Report. Clin Toxicol (Phila). 2018;56(12):1213–415. doi:
http://dx.doi.org/10.1080/15563650.2018.1533727. PubMed.
10 Tox Info Suisse. Jahresbericht 2017 Tox Info Suisse. 2017; Available
from: https://toxinfo.ch/customer/files/691/
9181408_Tox_JB-2017_DE_Website.pdf
11 Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning
severity score. Grading of acute poisoning. J Toxicol Clin Toxicol.
1998;36(3):205–13. doi: http://dx.doi.org/10.3109/
15563659809028940. PubMed.
12 Schurter D, Rauber-Lüthy C, Jahns M, Haberkern M, Kupferschmidt H,
Exadaktylos A, et al. Factors that trigger emergency physicians to con-
tact a poison centre: findings from a Swiss study. Postgrad Med J.
2014;90(1061):139–43. doi: http://dx.doi.org/10.1136/post-
gradmedj-2013-132242. PubMed.
13 Bundesamt für Gesundheit BAG. Suizidprävention in der Schweiz. Aus-
gangslage, Handlungsbedarf und Aktionsplan. 2016; Available from:
https://www.bag.admin.ch/bag/de/home/strategie-und-politik/politische-
auftraege-und-aktionsplaene/aktionsplan-suizidpraevention.html.
14 An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ.
2016;188(17-18):. doi: http://dx.doi.org/10.1503/cmaj.160357.
PubMed.
15 Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med.
2008;359(3):285–92. doi: http://dx.doi.org/10.1056/NEJMct0708278.
PubMed.
16 Tenenbein M. Whole bowel irrigation for toxic ingestions. J Toxicol
Clin Toxicol. 1985;23(2-3):177–84. doi: http://dx.doi.org/10.3109/
15563658508990626. PubMed.
17 Thanacoody R, Caravati EM, Troutman B, Höjer J, Benson B, Hoppu K,
et al. Position paper update: whole bowel irrigation for gastrointestinal
decontamination of overdose patients. Clin Toxicol (Phila).
2015;53(1):5–12. doi: http://dx.doi.org/10.3109/
15563650.2014.989326. PubMed.
18 Mengs U, Pohl RT, Mitchell T. Legalon® SIL: the antidote of choice in
patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm
Biotechnol. 2012;13(10):1964–70. doi: http://dx.doi.org/10.2174/
138920112802273353. PubMed.
19 Faulstich H, Jahn W, Wieland T. Silybin inhibition of amatoxin uptake
in the perfused rat liver. Arzneimittelforschung. 1980;30(3):452–4.
PubMed.
20 Thompson JP, Marrs TC. Hydroxocobalamin in cyanide poisoning. Clin
Toxicol (Phila). 2012;50(10):875–85. doi: http://dx.doi.org/10.3109/
15563650.2012.742197. PubMed.
21 Schaper A, Ebbecke M. Intox, detox, antidotes - Evidence based diagno-
sis and treatment of acute intoxications. Eur J Intern Med.
2017;45:66–70. doi: http://dx.doi.org/10.1016/j.ejim.2017.10.019.
PubMed.
22 König P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H.
Amantadine versus biperiden: a double-blind study of treatment efficacy
in neuroleptic extrapyramidal movement disorders. Neuropsychobiolo-
gy. 1996;33(2):80–4. doi: http://dx.doi.org/10.1159/000119254.
PubMed.
23 Ackland SP, Schilsky RL. High-dose methotrexate: a critical reap-
praisal. J Clin Oncol. 1987;5(12):2017–31. doi: http://dx.doi.org/
10.1200/JCO.1987.5.12.2017. PubMed.
24 Arens AM, Kearney T. Adverse Effects of Physostigmine. J Med Toxi-
col. 2019;15(3):184–91.
25 Vassilev ZP, Marcus SM. The impact of a poison control center on the
length of hospital stay for patients with poisoning. J Toxicol Environ
Health A. 2007;70(2):107–10. doi: http://dx.doi.org/10.1080/
15287390600755042. PubMed.
26 Spiller HA, Griffith JR. The value and evolving role of the U.S. Poison
Control Center System. Public Health Rep. 2009;124(3):359–63. doi:
http://dx.doi.org/10.1177/003335490912400303. PubMed.
27 Bunn TL, Slavova S, Spiller HA, Colvin J, Bathke A, Nicholson VJ.
The effect of poison control center consultation on accidental poisoning
inpatient hospitalizations with preexisting medical conditions. J Toxicol
Environ Health A. 2008;71(4):283–8. doi: http://dx.doi.org/10.1080/
15287390701738459. PubMed.
Original article Swiss Med Wkly. 2019;149:w20164
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 8 of 8
